Joe G. N. Garcia
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$11.1MFederal grants as PI16 awards
1Patents grantedLatest Oct 11, 2022
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
16 awards · $11.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 11, 2024 | NIH | SBIR Phase II A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | $958K | Aqualung Therapeutics Corp. |
| Jul 31, 2024 | NIH | STTR Phase II Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | $809K | Aqualung Therapeutics Corp. |
| Jul 16, 2024 | NIH | STTR Phase II Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | $975K | Aqualung Therapeutics Corp. |
| Sep 19, 2023 | NIH | STTR Phase II Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | $809K | Aqualung Therapeutics Corp. |
| Sep 8, 2023 | NIH | SBIR Phase II A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | $1.5M | Aqualung Therapeutics Corp. |
| Aug 15, 2023 | NIH | STTR Phase II Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | $975K | Aqualung Therapeutics Corp. |
| Sep 19, 2022 | NIH | STTR Phase II Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | $269K | Aqualung Therapeutics Corp. |
| Aug 29, 2022 | NIH | STTR Phase II Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | $260K | Aqualung Therapeutics Corp. |
| May 30, 2022 | NIH | STTR Phase II eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | $1.0M | Aqualung Therapeutics Corp. |
| Jun 1, 2021 | NIH | STTR Phase II eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | $1.0M | Aqualung Therapeutics Corp. |
| Apr 23, 2021 | NIH | STTR Phase II Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | $750K | Aqualung Therapeutics Corp. |
| Sep 18, 2020 | NIH | STTR Phase I Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP) | $265K | Aqualung Therapeutics Corp. |
| May 27, 2020 | NIH | STTR Phase II eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | $300K | Aqualung Therapeutics Corp. |
| May 12, 2020 | NIH | STTR Phase II Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | $750K | Aqualung Therapeutics Corp. |
| Aug 8, 2019 | NIH | STTR Phase I The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients | $225K | Aqualung Therapeutics Corp. |
| May 25, 2019 | NIH | STTR Phase II Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | $225K | Aqualung Therapeutics Corp. |
2 patents as inventor
- US 11466099Aqualung Therapeutics Corp.Oct 11, 2022
- US Aqualung Therapeutics Corp.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#52
Awards as PI#37
Patents#155
Companies
- Aqualung Therapeutics Corp.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.